Natalya Kovalyuk1, Igor Kaiserman1,2, Michael Mimouni3, Ornit Cohen1, Shmuel Levartovsky1,2, Hilda Sherbany4, Michal Mandelboim4,5. 1. Department of Ophthalmology, Barzilai Medical Center, Ashkelon, Israel. 2. Department of health science, Ben Gurion University, Be'er Sheva, Israel. 3. Department of Ophthalmology, Rambam Health Care Campus, Haifa, Israel. 4. Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Ramat-Gan, Israel. 5. Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Abstract
PURPOSE: To determine the efficacy of combination povidone-iodine (PVP-I) 1.0% eyedrops and dexamethasone 0.1% eyedrops in the treatment of adenoviral keratoconjunctivitis. MATERIALS AND METHODS: In a prospective, randomized, controlled, double-blinded clinical trial patients with recent adenoviral keratoconjunctivitis (diagnosed clinically and confirmed by PCR), we randomly divided into three treatment groups: study group - received PVP-I 1.0% and dexamethasone 0.1%, control 1 group - received dexamethasone 0.1% and control 2 group - received lubricating eyedrops (hypromellose 0.3%). The treatment was administered four times a day in each group. All patients were examined and filled a questionnaire before treatment and on the 3rd, 5th and 7th days of treatment. RESULTS: We included in the study 78 eyes (26 in each group). Adenovirus type 8 was the most common pathogen (83% of cases). The fastest improvement in patients red eyes, discharge, superficial punctate keratitis and pseudomembranes was observed in the study group (p < 0.001). Those patients reached a near complete recovery in 5-7 days, which was also confirmed by reduction in Adenovirus titres by PCR. The slowest improvement was in the control 2 group. Subepithelial infiltrates (SEI) were observed in 44% of the control 1 group, 20% of the control 2 group and in 0% of the study group. The rate of reduction in Adenovirus titres was the slowest in the control 1 group. CONCLUSION: The combination of PVP-I 1.0% and dexamethasone 0.1% four times a day can reduce symptoms and expedite recovery in epidemic keratoconjunctivitis patients.
RCT Entities:
PURPOSE: To determine the efficacy of combination povidone-iodine (PVP-I) 1.0% eyedrops and dexamethasone 0.1% eyedrops in the treatment of adenoviral keratoconjunctivitis. MATERIALS AND METHODS: In a prospective, randomized, controlled, double-blinded clinical trial patients with recent adenoviral keratoconjunctivitis (diagnosed clinically and confirmed by PCR), we randomly divided into three treatment groups: study group - received PVP-I 1.0% and dexamethasone 0.1%, control 1 group - received dexamethasone 0.1% and control 2 group - received lubricating eyedrops (hypromellose 0.3%). The treatment was administered four times a day in each group. All patients were examined and filled a questionnaire before treatment and on the 3rd, 5th and 7th days of treatment. RESULTS: We included in the study 78 eyes (26 in each group). Adenovirus type 8 was the most common pathogen (83% of cases). The fastest improvement in patients red eyes, discharge, superficial punctate keratitis and pseudomembranes was observed in the study group (p < 0.001). Those patients reached a near complete recovery in 5-7 days, which was also confirmed by reduction in Adenovirus titres by PCR. The slowest improvement was in the control 2 group. Subepithelial infiltrates (SEI) were observed in 44% of the control 1 group, 20% of the control 2 group and in 0% of the study group. The rate of reduction in Adenovirus titres was the slowest in the control 1 group. CONCLUSION: The combination of PVP-I 1.0% and dexamethasone 0.1% four times a day can reduce symptoms and expedite recovery in epidemic keratoconjunctivitispatients.
Authors: Ellen Shorter; Meredith Whiteside; Jennifer Harthan; Mathew S Margolis; Andrew T Hartwick; Spencer Johnson; Mary Migneco; Christina Morettin; Christian K Olson; Julia Huecker; Tammy Than; Mae O Gordon Journal: Ocul Surf Date: 2019-08-08 Impact factor: 5.033
Authors: Janusz Marcinkiewicz; Markus Nagl; Anthony Kyriakopoulos; Maria Walczewska; Magdalena Skóra; Paulina Skalska Journal: Adv Exp Med Biol Date: 2022 Impact factor: 3.650
Authors: Su-Hsun Liu; Barbara S Hawkins; Sueko M Ng; Mark Ren; Louis Leslie; Genie Han; Irene C Kuo Journal: Cochrane Database Syst Rev Date: 2022-03-03
Authors: Gabriella Ricciardelli; Giuseppe Giannaccare; Antonio Di Zazzo; Marco Coassin; Vincenzo Scorcia; Mario R Romano; Davide Allegrini; Michela Cennamo; Marco Antonini; Federico Bernabei; Alberto Morelli; Rita Mencucci Journal: Eye (Lond) Date: 2021-03-02 Impact factor: 3.775
Authors: C Cagini; M Mariniello; M Messina; A Muzi; C Balducci; A Moretti; L Levorato; A Mencacci Journal: Int Ophthalmol Date: 2020-07-22 Impact factor: 2.031